This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback
Trial record 4 of 5 for:    paratek

Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)

This study has been completed.
Information provided by (Responsible Party):
Paratek Pharmaceuticals Inc Identifier:
First received: July 14, 2015
Last updated: July 13, 2017
Last verified: July 2017
The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared to moxifloxacin in the treatment of adults with community-acquired bacterial pneumonia.

Condition Intervention Phase
Bacterial Pneumonia Community-Acquired Infections Drug: Omadacycline Drug: Moxifloxacin Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline Intravenous (IV)/Oral (PO) to Moxifloxacin IV/PO for Treating Adults Subjects With Community-Acquired Bacterial Pneumonia

Resource links provided by NLM:

Further study details as provided by Paratek Pharmaceuticals Inc:

Primary Outcome Measures:
  • Number of subjects with clinical success at the early clinical response assessment visit as defined by survival with improvement on 2 of 4 symptoms of community acquired bacterial pneumonia (CABP) [ Time Frame: 72-120 hours after first dose of study drug ]
    Symptoms include cough, sputum production, pleuritic chest pain and dyspnea

  • Number of subjects with clinical success at the post treatment evaluation visit defined as survival after test article completion and symptom resolution [ Time Frame: 5-10 days after the last day of therapy ]
    Symptoms include cough, sputum production, pleuritic chest pain and dyspnea

Enrollment: 774
Actual Study Start Date: November 2015
Study Completion Date: March 10, 2017
Primary Completion Date: February 5, 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Omadacycline
Omadacycline IV; Omadacycline tablets
Drug: Omadacycline
Injection for IV; Oral tablets
Active Comparator: Moxifloxacin
Moxifloxacin IV; Moxifloxacin tablets
Drug: Moxifloxacin
IV solution; Oral tablets
Other Name: Avelox


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients, ages 18 years or older who have signed the informed consent
  • Has qualifying bacterial pneumonia
  • Female patients must not be pregnant at the time of enrollment
  • Must agree to a reliable method of birth control during the study and for 30 days following the last dose of study drug

Exclusion Criteria:

  • Known or suspected hospital-acquired pneumonia
  • Evidence of significant immunological disease
  • Has a history of hypersensitivity or allergic reaction to any tetracycline or to any fluoroquinolone antibiotic
  • Has received an investigational drug within past 30 days
  • Women who are pregnant or nursing
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02531438

  Show 140 Study Locations
Sponsors and Collaborators
Paratek Pharmaceuticals Inc
  More Information

Responsible Party: Paratek Pharmaceuticals Inc Identifier: NCT02531438     History of Changes
Other Study ID Numbers: PTK0796-CABP-1200
Study First Received: July 14, 2015
Last Updated: July 13, 2017

Additional relevant MeSH terms:
Pneumonia, Bacterial
Community-Acquired Infections
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Bacterial Infections
Norgestimate, ethinyl estradiol drug combination
Anti-Bacterial Agents
Anti-Infective Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Contraceptives, Oral, Combined
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Nucleic Acid Synthesis Inhibitors processed this record on August 23, 2017